JOP20200003B1 - أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة - Google Patents
أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعةInfo
- Publication number
- JOP20200003B1 JOP20200003B1 JOP/2020/0003A JOP20200003A JOP20200003B1 JO P20200003 B1 JOP20200003 B1 JO P20200003B1 JO P20200003 A JOP20200003 A JO P20200003A JO P20200003 B1 JOP20200003 B1 JO P20200003B1
- Authority
- JO
- Jordan
- Prior art keywords
- bispecific antibodies
- checkpoint inhibitor
- inhibitor bispecific
- human
- antibodies
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 abstract 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012830 cancer therapeutic Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 102000048776 human CD274 Human genes 0.000 abstract 1
- 102000048362 human PDCD1 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
يتعلق الاختراع الحالي بأجسام مضادة دايمرية غير متجانسة وترتبط بـ PD-L1 بشري وPD-1 بشري، ويمكن أن تكون مفيدة في علاج السرطان بمفردها وفي توليفة مع العلاج الكيميائي وعلاجات السرطان الأخرى.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762530436P | 2017-07-10 | 2017-07-10 | |
PCT/US2018/041205 WO2019014091A1 (en) | 2017-07-10 | 2018-07-09 | BISPECIFIC ANTIBODIES AS INHIBITORS OF CONTROL POINTS |
Publications (2)
Publication Number | Publication Date |
---|---|
JOP20200003A1 JOP20200003A1 (ar) | 2020-01-07 |
JOP20200003B1 true JOP20200003B1 (ar) | 2023-03-28 |
Family
ID=63013165
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0003A JOP20200003B1 (ar) | 2017-07-10 | 2018-07-09 | أجسام مضادة ثنائية النوعية مثبطة لنقاط مراقبة المناعة |
Country Status (26)
Country | Link |
---|---|
US (1) | US11203640B2 (ar) |
EP (1) | EP3652216A1 (ar) |
JP (1) | JP6953612B2 (ar) |
KR (1) | KR102309950B1 (ar) |
CN (1) | CN110914306B (ar) |
AR (1) | AR112603A1 (ar) |
AU (1) | AU2018301326B2 (ar) |
BR (1) | BR112020000162A2 (ar) |
CA (1) | CA3069254C (ar) |
CL (1) | CL2020000053A1 (ar) |
CO (1) | CO2019015100A2 (ar) |
CR (1) | CR20190576A (ar) |
EA (1) | EA201992757A1 (ar) |
IL (1) | IL271347B2 (ar) |
JO (1) | JOP20200003B1 (ar) |
MA (1) | MA49563A (ar) |
MX (1) | MX2020000242A (ar) |
MY (1) | MY195071A (ar) |
NZ (1) | NZ760683A (ar) |
PE (1) | PE20200297A1 (ar) |
PH (1) | PH12020500075A1 (ar) |
SG (1) | SG11201911817VA (ar) |
TW (1) | TWI714864B (ar) |
UA (1) | UA126032C2 (ar) |
WO (1) | WO2019014091A1 (ar) |
ZA (1) | ZA201908549B (ar) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL265605B1 (en) | 2016-09-29 | 2024-02-01 | Beijing Hanmi Pharmaceutical Co Ltd | Heterodimeric immunoglobulin structures, a pharmaceutical preparation containing them, their use and methods for their preparation |
CN109963876B (zh) | 2016-11-18 | 2023-11-14 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
US11591409B2 (en) * | 2017-04-01 | 2023-02-28 | Beijing Hanmi Pharm. Co., Ltd. | Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN112334488B (zh) * | 2018-07-19 | 2023-12-08 | 伊莱利利公司 | 靶向免疫检查点的双特异性抗体 |
TWI760751B (zh) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
US11083705B2 (en) * | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 結合pd-1和pd-l1的雙特異性抗體的製劑及其用途 |
WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
WO2021226984A1 (zh) * | 2020-05-15 | 2021-11-18 | 三生国健药业(上海)股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
JP2023116826A (ja) * | 2020-05-20 | 2023-08-23 | 中外製薬株式会社 | 抗原結合分子 |
CN113754773A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业(上海)股份有限公司 | 一种抗pd1×pdl1的双特异性抗体 |
US11865082B2 (en) | 2020-09-09 | 2024-01-09 | Hoffmann-La Roche Inc. | Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 |
CN114601924A (zh) * | 2020-12-09 | 2022-06-10 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体或其抗原结合片段治疗鳞状非小细胞肺癌的方法 |
WO2023020315A1 (zh) * | 2021-08-19 | 2023-02-23 | 南京吉盛澳玛生物医药有限公司 | 靶向pd-l1/pd-1的抗体及其应用 |
WO2023040804A1 (zh) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和化疗药的药物组合及其使用方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO1998050431A2 (en) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
ES2395969T3 (es) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Dominios de proteínas heterodiméricas genéticamente modificados |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
EP3112382A1 (en) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Heterodimer binding proteins and uses thereof |
RU2012145183A (ru) | 2010-03-29 | 2014-05-10 | Займворкс, Инк. | Антитела с повышенной или пониженной эффекторной функцией |
JP6022444B2 (ja) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | ヘテロ二量体タンパク質ならびにそれを生産および精製するための方法 |
US10832794B2 (en) | 2010-09-24 | 2020-11-10 | Zymeworks Inc. | System for molecular packing calculations |
WO2012040833A1 (en) | 2010-09-30 | 2012-04-05 | Zymeworks Inc. | Simplifying residue relationships in protein design |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
PL2773671T3 (pl) | 2011-11-04 | 2022-01-24 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc |
WO2013096291A2 (en) | 2011-12-20 | 2013-06-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
US20150125449A1 (en) | 2012-05-10 | 2015-05-07 | Zymeworks Inc. | Single-Arm Monovalent Antibody Constructs and Uses Thereof |
WO2013166594A1 (en) | 2012-05-10 | 2013-11-14 | Zymeworks Inc. | Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain |
CN104640562A (zh) | 2012-07-13 | 2015-05-20 | 酵活有限公司 | 包含抗-cd3构建体的双特异性不对称异二聚体 |
IN2015DN01115A (ar) | 2012-07-13 | 2015-06-26 | Zymeworks Inc | |
US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
WO2014055784A1 (en) | 2012-10-03 | 2014-04-10 | Zymeworks Inc. | Methods of quantitating heavy and light chain polypeptide pairs |
EP2914634B1 (en) | 2012-11-02 | 2017-12-06 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
CA2893562C (en) | 2012-11-28 | 2023-09-12 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
CA2936785A1 (en) | 2014-01-15 | 2015-07-23 | Zymeworks Inc. | Bi-specific cd3 and cd19 antigen-binding constructs |
JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP4026850A1 (en) | 2014-05-28 | 2022-07-13 | Zymeworks Inc. | Modified antigen binding polypeptide constructs and uses thereof |
TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對pd-l1之抗體分子及其用途 |
JP6840127B2 (ja) * | 2015-07-29 | 2021-03-10 | ノバルティス アーゲー | がんの治療における抗pd−1抗体および抗m−csf抗体の併用 |
WO2017024465A1 (en) * | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
WO2017087547A1 (en) | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
-
2018
- 2018-06-26 AR ARP180101760 patent/AR112603A1/es unknown
- 2018-06-27 TW TW107121984A patent/TWI714864B/zh active
- 2018-07-09 AU AU2018301326A patent/AU2018301326B2/en active Active
- 2018-07-09 KR KR1020207000726A patent/KR102309950B1/ko active IP Right Grant
- 2018-07-09 JP JP2020500803A patent/JP6953612B2/ja active Active
- 2018-07-09 CR CR20190576A patent/CR20190576A/es unknown
- 2018-07-09 MY MYPI2020000114A patent/MY195071A/en unknown
- 2018-07-09 CN CN201880045977.1A patent/CN110914306B/zh active Active
- 2018-07-09 CA CA3069254A patent/CA3069254C/en active Active
- 2018-07-09 NZ NZ760683A patent/NZ760683A/en unknown
- 2018-07-09 WO PCT/US2018/041205 patent/WO2019014091A1/en active Search and Examination
- 2018-07-09 EA EA201992757A patent/EA201992757A1/ru unknown
- 2018-07-09 JO JOP/2020/0003A patent/JOP20200003B1/ar active
- 2018-07-09 PE PE2019002612A patent/PE20200297A1/es unknown
- 2018-07-09 MA MA049563A patent/MA49563A/fr unknown
- 2018-07-09 IL IL271347A patent/IL271347B2/en unknown
- 2018-07-09 US US16/029,979 patent/US11203640B2/en active Active
- 2018-07-09 EP EP18745803.9A patent/EP3652216A1/en active Pending
- 2018-07-09 SG SG11201911817VA patent/SG11201911817VA/en unknown
- 2018-07-09 BR BR112020000162-7A patent/BR112020000162A2/pt unknown
- 2018-07-09 MX MX2020000242A patent/MX2020000242A/es unknown
- 2018-07-09 UA UAA201912223A patent/UA126032C2/uk unknown
-
2019
- 2019-12-20 ZA ZA2019/08549A patent/ZA201908549B/en unknown
- 2019-12-30 CO CONC2019/0015100A patent/CO2019015100A2/es unknown
-
2020
- 2020-01-08 CL CL2020000053A patent/CL2020000053A1/es unknown
- 2020-01-09 PH PH12020500075A patent/PH12020500075A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
MY199019A (en) | Pd-1 antibodies | |
PH12019501253A1 (en) | Anti-tim-3 antibodies for combination with anti-pd-1 antibodies | |
TN2018000044A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
PH12019500369A1 (en) | Anti-tim-3 antibodies | |
PH12017500994A1 (en) | Anti-pd-1 antibodies and methods of use thereof | |
MY192999A (en) | Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists | |
MX2020006668A (es) | Anticuerpos para lilrb2. | |
PH12020500225A1 (en) | Anti- cd137 antibodies | |
BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
EP3954713A3 (en) | Bispecific antibodies that bind to cd38 and cd3 | |
PH12019502313A1 (en) | Anti-pd-l1-anti-tim-3 bispecific antibodies | |
MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. | |
MX2020009863A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1. | |
MX2020006125A (es) | Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer. |